Alexar Therapeutics was formed by NeXeption to develop an innovative portfolio of Liver X receptor (LXR) agonists for both systemic and local dermatologic use. Its lead program, A-110, is a topical LXR agonist being developed for inflammatory cutaneous disorders. The company intends to use proceeds from its Series A to fund initial development of A-110 and advance the broader LXR portfolio. NeXeption’s business model creates independent operating companies focused on maximizing the value of individual assets and moving them efficiently from concept to partnership or launch. Leadership announced includes CEO Dave Pfeiffer, Chairman Steve Tullman, and Vice Chairman Dr. Neal Walker, with investor representation on the board. Management and company statements highlight potential applicability of the LXR portfolio to multiple dermatology indications and other therapeutic areas.

Total raised

$22M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2014